Fig 1: Abundances of immune populations in single-cell suspensions A UMAP of included samples, B UMAP of lymphoid and myeloid cells, and tumor and non-lesional tissue, C ratio between lymphoid and myeloid cells in tumor versus non-lesional tissue, D ratio between M1 and M2 macrophages in tumor versus non-lesional tissue, E percentage of CD169+ macrophages of total cells in patients with PDAC who received neoadjuvant therapy versus those who did not receive neoadjuvant therapy, F percentage of CD4 of total cells in tumor tissue of patients with PDAC with < 18-month survival and ≥ months survival , G abundances in tumor of PDAC survival CD4 (H) percentage of CD88+CD16high of total cells in tumor tissue of patients with PDAC with < 18-month survival and ≥ months survival I percentage of DC3 of total cells in tumor tissue of patients with PDAC with < 18-month survival and ≥ months survival , H percentage of M1 macrophages of total cells in tumor tissue of patients with PDAC with < 18-month survival and ≥ months survival boxplots: black bar denotes median, box denotes the interquartile range, whiskers indicate the range of values that are outside of the interquartile range. Outliers are defined as > 1.5 times the size of the interquartile range and presented as a*
Supplier Page from Novus Biologicals, a Bio-Techne Brand for Siglec-1/CD169 Antibody (HSn 7D2) [Alexa Fluor® 647]
Available conjugates: Available conjugates: Alexa Fluor 532, Alexa Fluor 647Sizes Available: 0.1 ml